Summary

According to the recently published report ’N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019’; N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) pipeline Target constitutes close to 8 molecules.

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor (GPCR) encoded by the FPR2 gene and is activated to regulate cell function by binding to a wide variety of ligands like N-Formylmethionine-containing oligopeptides such as N-Formylmethionine-leucyl-phenylalanine (FMLP), polyunsaturated fatty acid metabolite of arachidonic acid, lipoxin A4 (LXA4). FPR2 mediates responses to a wide range of polypeptides and proteins which may serve to promote inflammation.

The report ’N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019’ outlays comprehensive information on the N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 2 and 6 respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Immunology, Dermatology, Gastrointestinal, Infectious Disease, Metabolic Disorders and Oncology which include indications Inflammation, Alzheimer’s Disease, Atherosclerosis, Atopic Dermatitis (Atopic Eczema), Cardiovascular Disease, Congestive Heart Failure (Heart Failure), Crohn’s Disease (Regional Enteritis), Fungal Infections, Ischemia Reperfusion Injury, Ischemic Stroke, Metastatic Cancer, Multiple Sclerosis, Myocardial Infarction, Myocardial Ischemia, Staphylococcus aureus Infections and Type 2 Diabetes.


Scope

  • The report provides a snapshot of the global therapeutic landscape for N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
  • The report reviews N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics




Reasons To Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope